The AstraZeneca share price just fell 8.4% in a day. Is it time to consider buying?

The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge fall?

| More on:
Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price is in freefall at the moment. Yesterday (5 November), it fell 8.4%. Since late August, it has plummeted nearly 25%.

So, what’s going on here? And has the share price created a good buying opportunity for long-term investors to consider?

Share price crash

Let’s start with yesterday’s fall.

It seems this was primarily caused by a report that a number of senior executives at the pharma company’s China unit could be implicated in a major insurance fraud case.

Last week, AstraZeneca said that its China president Leon Wang was being investigated by authorities and would be standing down from his position.

However, according to financial media company Yicai, the investigation by Chinese authorities has now blown out to include ‘dozens’ of senior AstraZeneca executives, with multiple authorities getting involved.

It’s worth noting that problems in China have been plaguing the company for months now. In early September, police in the country detained five current and former employees of AstraZeneca for questioning about potential illegal activities. This issue was related to its collection of patient data and whether it infringed China’s data-privacy laws.

Sell rating

Another factor that has hurt the FTSE 100 stock in recent months is disappointing drug trial results. In mid-September, the shares fell after results from the company’s lung cancer trials showed that its experimental precision drug didn’t significantly improve overall survival results for patients.

Finally, there has been some negative broker commentary recently. For example, in September, analysts at Deutsche Bank slapped a Sell rating on the stock. It’s worth noting that yesterday, the same analysts described early data on AstraZeneca’s experimental weight loss pill as “somewhat underwhelming”.

So overall, there has been a lot of negative news for investors to digest here.

A buying opportunity?

But is now a good time to take a closer look at the stock?

My gut feeling is that it is.

The China issues are certainly a risk factor here. They could lead to reputational damage and/or large fines and put more pressure on the share price in the near term.

But I think the company can recover from these setbacks. I don’t think that they’re likely to impact the group too much in the long run.

As for the disappointing drug trial results, I don’t see these as the end of the world for the firm. That’s because AstraZeneca currently has nearly 200 drugs in its pipeline.

Turning to the valuation, the shares currently trade on a forward-looking price-to-earnings (P/E) ratio of about 14 after yesterday’s fall. That’s a relatively attractive valuation, in my view.

It’s worth pointing out that trying to ‘catch a falling knife’ can be dangerous. That’s because a stock in freefall can keep falling.

So, if I was interested in buying the stock, I would probably wait until it had stabilised a little. I’d also look to build a position over time and average out my entry prices.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Growth Shares

Investing Articles

3 champion investments to beat the stock market in 2025

Looking for alpha? Dr James Fox details three investments that look destined to outperform the stock market in 2025 and…

Read more »

Investing Articles

The Rolls-Royce share price hit new highs in November. What next?

November has been another record-breaking month for the Rolls-Royce share price. And the outlook for 2025 still looks bright.

Read more »

Investing Articles

Here’s the growth forecast for Sage Group shares to 2026!

Sage Group shares have rocketed following the tech firm's stunning third-quarter update. Is now the time to consider buying in?

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »